Moreover, we confirmed the establishment of an epigenetic dynamic interplay between the BAP1/ASXL3 complex and the opposing ncPRC1 complex, which could potentially be targeted for developing other therapeutics in order to increase the effectiveness against SCLC tumor progression. The gene discussed is ASXL3; the disease is neoplasm.